Evidence map›Paper›PMID 39125297›Full record

ArticleNutrients2024

Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer.

Sheila Almaraz-Postigo, Eduardo Sanz, Atanasio Pandiella, Elena Díaz-Rodríguez

Abstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sheila Almaraz-PostigoInstituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Instituto de Investigación Biomédica de Salamanca (IBSAL) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Campus Miguel de Unamuno, 37007 Salamanca, Spain.
Eduardo SanzCatalysis S.L., 28016 Madrid, Spain.
Atanasio PandiellaInstituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Instituto de Investigación Biomédica de Salamanca (IBSAL) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Campus Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0002-4704-8971
Elena Díaz-RodríguezInstituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Instituto de Investigación Biomédica de Salamanca (IBSAL) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Campus Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0002-6240-6327

Funding

Consejería de Educación de la Junta de Castilla y León CSI146P20Instituto de Salud Carlos III CB16/12/00317Ministry of Economy and Competitiveness of Spain BFU2015-71371-R and PID2020-115605RB-I00
6 · The paper itself

Abstract

Ovarian cancer is the most fatal of all the reproductive cancers within the female population, mainly due to its late diagnosis that limits surgery and medical treatment. Classically, ovarian cancer therapy has included conventional chemotherapy, and other therapeutic approaches are now being used to treat these patients, but the outcomes of the disease are still poor. Therefore, new strategies are needed to improve life expectancy and life quality of ovarian cancer patients. Considering that, we investigated the effect of the nutritional supplement Ocoxin Oral Solution (OOS) in ovarian cancer models. OOS contains several nutritional supplements, some of them with demonstrated antitumoral action.

Indexed as

Cell ProliferationDNA DamageOvarian NeoplasmsAdministration, OralAnimalsAntineoplastic AgentsAscorbic AcidCell DeathCell Line, TumorDietary SupplementsFemaleFolic AcidHistonesHumansMicePantothenic AcidAntineoplastic AgentsAscorbic AcidFolic AcidHistonesOcoxinPantothenic AcidPlant ExtractsPyridoxineVitamin B 12Vitamin B 6Zinc Sulfateantioxidantscell deathDNA damageOOSovarian cancer

Identifiers

PMID39125297
PMCPMC11313973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.